580 related articles for article (PubMed ID: 21211680)
1. [Enzyme replacement therapy of lysosomal storage diseases].
Germain DP; Boucly C; Carlier RY; Caudron E; Charlier P; Colas F; Jabbour F; Martinez V; Mokhtari S; Orlikowski D; Pellegrini N; Perronne C; Prigent H; Rubinsztajn R; Benistan K
Rev Med Interne; 2010 Dec; 31 Suppl 2():S279-91. PubMed ID: 21211680
[TBL] [Abstract][Full Text] [Related]
2. Therapy for the mucopolysaccharidoses.
Valayannopoulos V; Wijburg FA
Rheumatology (Oxford); 2011 Dec; 50 Suppl 5():v49-59. PubMed ID: 22210671
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.
Wyatt K; Henley W; Anderson L; Anderson R; Nikolaou V; Stein K; Klinger L; Hughes D; Waldek S; Lachmann R; Mehta A; Vellodi A; Logan S
Health Technol Assess; 2012; 16(39):1-543. PubMed ID: 23089251
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy for the management of the mucopolysaccharidoses.
Wraith JE
Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S63-5. PubMed ID: 20040314
[TBL] [Abstract][Full Text] [Related]
5. Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS).
Spataro F; Viggiani F; Macchia DG; Rollo V; Tummolo A; Suppressa P; Sabba' C; Rossi MP; Giliberti L; Satriano F; Nettis E; Di Bona D; Caiaffa MF; Fischetto R; Macchia L
Orphanet J Rare Dis; 2022 Nov; 17(1):402. PubMed ID: 36329518
[TBL] [Abstract][Full Text] [Related]
6. Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders.
Miebach E
Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S100-6. PubMed ID: 20040319
[TBL] [Abstract][Full Text] [Related]
7. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
Whiteman DA; Kimura A
Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
[TBL] [Abstract][Full Text] [Related]
8. Treating lysosomal storage disorders: What have we learnt?
Lachmann RH
J Inherit Metab Dis; 2020 Jan; 43(1):125-132. PubMed ID: 31140601
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
Brunelli MJ; Atallah ÁN; da Silva EM
Cochrane Database Syst Rev; 2016 Mar; 3():CD009806. PubMed ID: 26943923
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Remmington T
Cochrane Database Syst Rev; 2016 Apr; 4():CD009354. PubMed ID: 27033167
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.
Ruane T; Haskins M; Cheng A; Wang P; Aguirre G; Knox VW; Qi Y; Tompkins T; O'Neill CA
Mol Genet Metab; 2016 Feb; 117(2):157-63. PubMed ID: 26776148
[TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures.
Harmatz P
Turk J Pediatr; 2010; 52(5):443-9. PubMed ID: 21434527
[TBL] [Abstract][Full Text] [Related]
13. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
[TBL] [Abstract][Full Text] [Related]
14. The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
Harmatz P; Hendriksz CJ; Lampe C; McGill JJ; Parini R; Leão-Teles E; Valayannopoulos V; Cole TJ; Matousek R; Graham S; Guffon N; Quartel A;
Mol Genet Metab; 2017 Sep; 122(1-2):107-112. PubMed ID: 28457718
[TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Wraith JE
Cochrane Database Syst Rev; 2013 Nov; (11):CD009354. PubMed ID: 24257962
[TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Wraith JE
Cochrane Database Syst Rev; 2013 Sep; (9):CD009354. PubMed ID: 24085657
[TBL] [Abstract][Full Text] [Related]
17. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses.
Muenzer J
Mol Genet Metab; 2014 Feb; 111(2):63-72. PubMed ID: 24388732
[TBL] [Abstract][Full Text] [Related]
18. Lysosomal storage diseases.
Manwaring LP; Jamerson PA; Slaugh R
RN; 2008 Jul; 71(7):33-7; quiz 38. PubMed ID: 18720909
[No Abstract] [Full Text] [Related]
19. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)--10-year follow-up of patients who previously participated in an MPS VI Survey Study.
Giugliani R; Lampe C; Guffon N; Ketteridge D; Leão-Teles E; Wraith JE; Jones SA; Piscia-Nichols C; Lin P; Quartel A; Harmatz P
Am J Med Genet A; 2014 Aug; 164A(8):1953-64. PubMed ID: 24764221
[TBL] [Abstract][Full Text] [Related]
20. Enzyme reconstitution/replacement therapy for lysosomal storage diseases.
Burrow TA; Hopkin RJ; Leslie ND; Tinkle BT; Grabowski GA
Curr Opin Pediatr; 2007 Dec; 19(6):628-35. PubMed ID: 18025928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
